Evofem Biosciences executed a fourth amendment to its existing Securities Purchase Agreement with Adjuvant Global Health Technology Fund. The amendment establishes a new maturity date for the company's convertible promissory notes. The notes are now due on the earliest of: six months from April 10, 2026, the date of a Change of Control, or upon acceleration per the agreement. Prepayment of the notes is restricted for six months from the effective date without prior written consent from the lenders.